Nightingale Health Oyj (HEL:HEALTH)
Finland · Delayed Price · Currency is EUR | Market Cap | 66.40M -60.7% |
| Revenue (ttm) | 4.80M -3.2% |
| Net Income | -19.07M |
| EPS | -0.32 |
| Shares Out | 60.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,476 |
| Average Volume | 41,759 |
| Open | 1.100 |
| Previous Close | 1.100 |
| Day's Range | 1.095 - 1.140 |
| 52-Week Range | 1.085 - 2.995 |
| Beta | 0.32 |
| RSI | 29.91 |
| Earnings Date | Jun 3, 2026 |
About Nightingale Health Oyj
Nightingale Health Oyj, a health technology company, offers advanced health check that detects disease risks in Finland, the United Kingdom, rest of Europe, the United States, and internationally. The company’s Health Check that detects the risks associated with various common chronic diseases from a single blood sample; and Remote Health Check where health check done remotely. It also offers blood analysis, self collection kits, urine analysis, and biomarkers services. It provides its services to research programs, universities, and healthcare... [Read more]
Financial Performance
In fiscal year 2025, Nightingale Health Oyj's revenue was 4.69 million, an increase of 7.69% compared to the previous year's 4.36 million. Losses were -18.46 million, 5.71% more than in 2024.
Financial StatementsNews
Nightingale Health Oyj Earnings Call Transcript: H1 2026
Revenue grew 4% in H1, with strong order book and pilots supporting a reiterated 50% full-year growth target. Major partnerships expanded, new contracts secured, and US market entry advanced with the New York lab permit. H2 focus is on targeted sales and commercial scaling.
Nightingale Health Oyj Earnings Call Transcript: H2 2025
Revenue grew 8% year-over-year to €4.7 million, with strong liquidity and no debt. Major milestones included a public sector deal in Finland, U.S. lab expansion, and a new multi-omics research contract. The outlook targets at least 50% revenue growth this year.
Nightingale Health Oyj Earnings Call Transcript: H1 2025
Revenue grew 35% year-over-year to €2.3 million, with improved profitability and a strong €60 million liquidity position. Expansion continued in key markets, new labs were established, and commercial launches are imminent in Singapore and the U.S.
Nightingale Health Oyj Earnings Call Transcript: H2 2024
Revenue grew 4% year-over-year to EUR 4.36 million, with strong progress in international expansion and major healthcare partnerships. The company remains debt-free, maintains a solid cash position, and is focused on scaling adoption and achieving positive EBITDA.